Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about EXOZ, unsubscribe in one click. Privacy
EXOZ holds $5.7M in cash and short-term investments (as of Jun 30, 2026) and burns about $1.6M/quarter from operations, an estimated runway of 10.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 52 · Elevated
Given the Company’s current operating cash burn, its existing working capital as of June 30, 2026, is not sufficient to fund operations for twelve months from the date these condensed unaudited consolidated financial statements are issued, and management has concluded that substantial doubt exists about the Company’s a10-Q, Aug 2026
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when EXOZ files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for EXOZ and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →